RRML - Factors influencing vitamin K antagonists therapy
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12


Advanced search


Top 10 downloaded articles
- November 2024 -
 
Towards appropriate training f... 31
Recomandările naționale ale ... 28
Biomarkers of acute kidney inj... 23
A comprehensive review of glyc... 20
Agreement between different eG... 19
Investigation of cytokine chan... 19
Expressions of vascular endoth... 17
Role of Th1/Th2 imbalance medi... 16
Small patients, big challenges... 9
The frequency of EGFR gene mut... 8

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 23(2)/2015 DOI:10.1515/rrlm-2015-0015
XML
TXT

Factors influencing vitamin K antagonists therapy

Ioana Brudașcă


Abstract:

Vitamin K antagonists (VKAs) are widely used for the primary and secondary prevention of thromboembolism, their anticoagulant effect being monitored through INR. Achieving and maintaining a stable anticoagulation status is challenging, because of the narrow therapeutic range, and of the extremely variable individual response to therapy. Environmental factors such as age, gender, body mass, diet, herbal supplements, drugs, pre-existing pathology, as well as genetic factors can substantially influence the anticoagulant effect of VKAs. The main genetic factors that contribute to individual variability in response to VKAs are genetic polymorphisms in genes influencing VKAs’ metabolism (CYP2C9) and pharmacodynamic response (VKOR1) and account for about one third in the variation of warfarin and analogues dose requirement. Systematic genotyping of patients requiring warfarin therapy is still a matter of debate. Although novel oral anticoagulants (direct thrombin and factor Xa inhibitors) seem promising, VKAs are still frequently prescribed, therefore physicians should be aware of the various factors influencing VKAs’ effect, and educational programmes for doctors and patients should be conducted in that respect.

Keywords: Vitamin K antagonists, warfarin, drug interactions, genotyping CYP2C9 , VKORC1

Received: 10.2.2015
Accepted: 15.5.2015
Published: 1.6.2015

 
  PDF Download full text PDF
(344 KB)
     
 
How to cite
Brudașcă I. Factors influencing vitamin K antagonists therapy. Rev Romana Med Lab. 2015;23(2):159-67. DOI:10.1515/rrlm-2015-0015